Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,040 | 1 | 58.9% |
| Travel and Lodging | $1,878 | 4 | 22.0% |
| Unspecified | $1,432 | 4 | 16.7% |
| Food and Beverage | $106.60 | 3 | 1.2% |
| Education | $99.99 | 1 | 1.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Insmed, Inc. | $8,457 | 12 | $0 (2024) |
| Genentech USA, Inc. | $99.99 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,996 | 7 | Insmed, Inc. ($6,996) |
| 2023 | $1,432 | 4 | Insmed, Inc. ($1,432) |
| 2019 | $128.99 | 2 | Genentech USA, Inc. ($99.99) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,040.00 | General |
| 12/19/2024 | Insmed, Inc. | — | Food and Beverage | In-kind items and services | $48.20 | General |
| 12/12/2024 | Insmed, Inc. | — | Travel and Lodging | In-kind items and services | $235.52 | General |
| 12/12/2024 | Insmed, Inc. | — | Travel and Lodging | In-kind items and services | $212.38 | General |
| 12/08/2024 | Insmed, Inc. | — | Travel and Lodging | In-kind items and services | $541.68 | General |
| 11/12/2024 | Insmed, Inc. | — | Travel and Lodging | In-kind items and services | $888.74 | General |
| 03/08/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Respiratory | ||||||
| 01/26/2023 | Insmed, Inc. | Arikayce (Drug) | — | In-kind items and services | $591.21 | Research |
| Category: Respiratory | ||||||
| 01/26/2023 | Insmed, Inc. | Arikayce (Drug) | — | In-kind items and services | $352.26 | Research |
| Category: Respiratory | ||||||
| 01/26/2023 | Insmed, Inc. | Arikayce (Drug) | — | In-kind items and services | $327.55 | Research |
| Category: Respiratory | ||||||
| 01/26/2023 | Insmed, Inc. | Arikayce (Drug) | — | In-kind items and services | $160.72 | Research |
| Category: Respiratory | ||||||
| 05/20/2019 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Respiratory | ||||||
| 05/19/2019 | Genentech USA, Inc. | Esbriet (Biological) | Education | In-kind items and services | $99.99 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 755 | 899 | $486,543 | $69,524 |
| 2022 | 11 | 719 | 829 | $410,320 | $51,046 |
| 2021 | 11 | 893 | 1,077 | $485,860 | $75,967 |
| 2020 | 11 | 759 | 904 | $339,698 | $60,562 |
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 91 | 182 | $337,246 | $33,989 | 10.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 47 | $22,179 | $5,291 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 37 | 44 | $12,823 | $5,263 | 41.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 26 | $19,682 | $4,158 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 40 | 47 | $10,390 | $4,050 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 40 | $13,682 | $3,134 | 22.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 28 | $10,367 | $3,058 | 29.5% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 20 | 29 | $22,417 | $2,756 | 12.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $5,564 | $2,666 | 47.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 13 | $3,510 | $943.76 | 26.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 76 | 78 | $4,173 | $565.16 | 13.5% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 61 | 63 | $3,561 | $500.96 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 15 | $2,961 | $488.00 | 16.5% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Facility | 2023 | 15 | 15 | $2,235 | $483.08 | 21.6% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 46 | 46 | $3,368 | $441.16 | 13.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 52 | 53 | $2,983 | $431.25 | 14.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 46 | 46 | $2,710 | $412.28 | 15.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 31 | 31 | $2,324 | $328.50 | 14.1% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 40 | 42 | $2,340 | $314.16 | 13.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 36 | 38 | $2,028 | $250.24 | 12.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 55 | 118 | $218,654 | $22,434 | 10.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 62 | $22,816 | $5,694 | 25.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 36 | $17,760 | $4,469 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 28 | 33 | $9,106 | $4,013 | 44.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $11,122 | $2,870 | 25.8% |
About Dr. Meghan Marmor, MD
Dr. Meghan Marmor, MD is a Pulmonary Disease healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2013. The National Provider Identifier (NPI) number assigned to this provider is 1003253147.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Meghan Marmor, MD has received a total of $8,557 in payments from pharmaceutical and medical device companies, with $6,996 received in 2024. These payments were reported across 13 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($5,040).
As a Medicare-enrolled provider, Marmor has provided services to 3,126 Medicare beneficiaries, totaling 3,709 services with total Medicare billing of $257,099. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Internal Medicine, Critical Care Medicine
- Location Stanford, CA
- Active Since 05/30/2013
- Last Updated 04/15/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1003253147
Products in Payments
- Arikayce (Drug) $1,490
- Esbriet (Biological) $99.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Stanford
Revati Shreeniwas, Md, MD
Pulmonary Disease — Payments: $1.5M
Roham Zamanian, Md, MD
Pulmonary Disease — Payments: $76,614
Harmeet Bedi, Md, MD
Pulmonary Disease — Payments: $38,291
Ramona Doyle, M.d, M.D
Pulmonary Disease — Payments: $25,968
Dr. Gaurav Singh, M.d,, M.D,
Pulmonary Disease — Payments: $20,426
Angela Rogers, M.d, M.D
Pulmonary Disease — Payments: $3,575